Author

V. C. Pham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Organism:Drosophila· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Ashworth· 1 shared A. Dey· 1 shared A. Fossoul· 1 shared B. Antonny· 1 shared B. L. Lee· 1 shared B. Mesmin· 1 shared C. E. Stivala· 1 shared C. L. Noland· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ashworth

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation

T. H. Pham, K. B. Pahuja, T. J. Hagenbeek, J. Zbieg, C. L. Noland, V. C. Pham, X. Yao, C. M. Rose, K. C. Browder, H.-J. Lee, M. Yu, M. Liang-Chu, S. E. Martin, E. Verschueren, J. Li, , A. Dey

This study identifies RNF146 as an E3 ubiquitin ligase that degrades TEAD proteins via the proteasome, showing that pharmacological induction of TEAD ubiquitination can suppress YAP/TAZ-driven cancer growth.

bioRxiv · Oct 3, 2023 · PreprintCancer Biology

Molecular and cellular dissection of the OSBP cycle through a fluorescent inhibitor

T. Péresse, D. Kovacs, M. Subra, J. Bigay, M.-C. Tsai, J. Polidori, R. Gautier, S. Desrat, L. Fleuriot, D. Debayle, M. Litaudon, V. C. Pham, J. Bignon, B. Antonny, F. Roussi, B. Mesmin

The paper uses a fluorescent inhibitor to study OSBP lipid exchange and its effects on cellular processes.

bioRxiv · Nov 20, 2019 · PreprintCell Biology

MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition

L. Vande Walle, I. B. Stowe, P. Sacha, B. L. Lee, D. Demon, A. Fossoul, F. Van Hauwermeiren, P. H. V. Saavedra, P. Simon, V. Subrt, L. Kostka, C. E. Stivala, V. C. Pham, S. T. Staben, S. Yamazoe, , M. Lamkanfi

This study identifies the NACHT domain of wildtype NLRP3 as the target of MCC950/CRID3, showing it inhibits inflammasome activity but not CAPS-associated mutants.

bioRxiv · May 11, 2019Immunology